Director Gylvin Lykke Buys 14,495 ProQR Options, Signaling Long‑Term Confidence in the Biotech Pipeline
ProQR insider Lykke buys 14,495 options, signaling confidence in the company’s gene‑therapy pipeline and potential upside amid market volatility.
2 minutes to read